Cargando…
Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease
Chronic kidney disease, despite being a “silent epidemic” disease, represents one of the main causes of mortality in general population, along with cardiovascular disease, which is the leading cause of poor prognosis for these patients. The specific objective of our study was to characterize the rel...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030443/ https://www.ncbi.nlm.nih.gov/pubmed/27667892 http://dx.doi.org/10.1155/2016/3185232 |
_version_ | 1782454681012797440 |
---|---|
author | Mihai, Simona Codrici, Elena Popescu, Ionela Daniela Enciu, Ana-Maria Rusu, Elena Zilisteanu, Diana Albulescu, Radu Anton, Gabriela Tanase, Cristiana |
author_facet | Mihai, Simona Codrici, Elena Popescu, Ionela Daniela Enciu, Ana-Maria Rusu, Elena Zilisteanu, Diana Albulescu, Radu Anton, Gabriela Tanase, Cristiana |
author_sort | Mihai, Simona |
collection | PubMed |
description | Chronic kidney disease, despite being a “silent epidemic” disease, represents one of the main causes of mortality in general population, along with cardiovascular disease, which is the leading cause of poor prognosis for these patients. The specific objective of our study was to characterize the relationship between the inflammatory status, the bone disorders markers, and kidney failure in chronic kidney disease patient stages 2–4, in order to design a novel biomarker panel that improves early disease diagnosis and therapeutic response, thus being further integrated into clinical applications. A panel of proteomic biomarkers, assessed by xMAP array, which includes mediators of inflammation (IL-6, TNF-α) and mineral and bone disorder biomarkers (OPG, OPN, OCN, FGF-23, and Fetuin-A), was found to be more relevant than a single biomarker to detect early CKD stages. The association between inflammatory cytokines and bone disorders markers, IL-6, TNF-α, OPN, OPG, and FGF-23, reflects the severity of vascular changes in CKD and predicts disease progression. Proteomic xMAP analyses shed light on a new approach to clinical evaluation for CKD staging and prognosis. |
format | Online Article Text |
id | pubmed-5030443 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-50304432016-09-25 Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease Mihai, Simona Codrici, Elena Popescu, Ionela Daniela Enciu, Ana-Maria Rusu, Elena Zilisteanu, Diana Albulescu, Radu Anton, Gabriela Tanase, Cristiana Dis Markers Research Article Chronic kidney disease, despite being a “silent epidemic” disease, represents one of the main causes of mortality in general population, along with cardiovascular disease, which is the leading cause of poor prognosis for these patients. The specific objective of our study was to characterize the relationship between the inflammatory status, the bone disorders markers, and kidney failure in chronic kidney disease patient stages 2–4, in order to design a novel biomarker panel that improves early disease diagnosis and therapeutic response, thus being further integrated into clinical applications. A panel of proteomic biomarkers, assessed by xMAP array, which includes mediators of inflammation (IL-6, TNF-α) and mineral and bone disorder biomarkers (OPG, OPN, OCN, FGF-23, and Fetuin-A), was found to be more relevant than a single biomarker to detect early CKD stages. The association between inflammatory cytokines and bone disorders markers, IL-6, TNF-α, OPN, OPG, and FGF-23, reflects the severity of vascular changes in CKD and predicts disease progression. Proteomic xMAP analyses shed light on a new approach to clinical evaluation for CKD staging and prognosis. Hindawi Publishing Corporation 2016 2016-09-07 /pmc/articles/PMC5030443/ /pubmed/27667892 http://dx.doi.org/10.1155/2016/3185232 Text en Copyright © 2016 Simona Mihai et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Mihai, Simona Codrici, Elena Popescu, Ionela Daniela Enciu, Ana-Maria Rusu, Elena Zilisteanu, Diana Albulescu, Radu Anton, Gabriela Tanase, Cristiana Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease |
title | Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease |
title_full | Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease |
title_fullStr | Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease |
title_full_unstemmed | Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease |
title_short | Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease |
title_sort | proteomic biomarkers panel: new insights in chronic kidney disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030443/ https://www.ncbi.nlm.nih.gov/pubmed/27667892 http://dx.doi.org/10.1155/2016/3185232 |
work_keys_str_mv | AT mihaisimona proteomicbiomarkerspanelnewinsightsinchronickidneydisease AT codricielena proteomicbiomarkerspanelnewinsightsinchronickidneydisease AT popescuioneladaniela proteomicbiomarkerspanelnewinsightsinchronickidneydisease AT enciuanamaria proteomicbiomarkerspanelnewinsightsinchronickidneydisease AT rusuelena proteomicbiomarkerspanelnewinsightsinchronickidneydisease AT zilisteanudiana proteomicbiomarkerspanelnewinsightsinchronickidneydisease AT albulescuradu proteomicbiomarkerspanelnewinsightsinchronickidneydisease AT antongabriela proteomicbiomarkerspanelnewinsightsinchronickidneydisease AT tanasecristiana proteomicbiomarkerspanelnewinsightsinchronickidneydisease |